|
1) Iwashima S, Maruyama S, Matsuo S, et al. Novel culture system of mesenchymal stromal cells from human subcutaneous adipose tissue. Stem Cells and Development. 2009; 18: 533-43
|
|
|
|
2) Kuroda Y, Kitada M, Dezawa M, et al. Unique multipotent cells in adult human mesenchymal cell populations. PNAS. 2010; 107: 8639-43
|
|
|
|
|
|
3) Saka Y, Furuhashi K, Maruyama S, et al. Adipose-derived stromal cells cultured in a low serum medium, but not bone-marrow derived stromal cells, impede xenoantibody production. Xenotransplantation. 2011; in press
|
|
|
|
|
|
4) Ren G, Zhang L, Shi Y, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-50
|
|
|
|
|
|
5) Stagg J, Pommey S, Eliopoulos N, et al. Interferon-γ-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood. 2006; 107: 2570-7
|
|
|
|
|
|
6) Nemeth K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009; 15: 42-9
|
|
|
|
|
|
7) English K, Barry FP, Mahon BP, et al. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett. 2007; 110: 91-100
|
|
|
|
|
|
8) Ren G, Zhang L, Shi Y, et al. Mesenchymal stem cell-mediated immunosuppression occur via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008; 2: 141-50
|
|
|
|
|
|
9) Ren G, Su J, Shi Y, et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells. 2009; 27: 1954-62
|
|
|
|
|
|
10) Di Nicola M, Carlo-stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002; 99: 3838-43
|
|
|
|
|
|
11) Glennie S, Soeiro I, Dazzi F, et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood. 2005; 105: 2821-7
|
|
|
|
|
|
12) Zappia E, Casazza S, Pedemonte E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005; 106: 1755-61
|
|
|
|
|
|
13) Liotta F, Angeli R, Annunziato F, et al. Toll-like receptor 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells. 2008; 26: 279-89
|
|
|
|
|
|
14) Spaggiari GM, Capobianco A, Moretta L, et al. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood. 2006; 107: 1484-90
|
|
|
|
|
|
15) Spaggiari GM, Capobianco A, Moretta L, et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2. Blood. 2008; 111: 1327-33
|
|
|
|
|
|
16) Djouad F, Charbonnier LM, Noël D, et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells. 2007; 25: 2025-32
|
|
|
|
|
|
17) Chen L, Zhang W, et al. Effects of human mesenchymal stem cells on the differentiation of dendritic cells from CD34 cells. Stem Cells Dev. 2007; 16: 719-31
|
|
|
|
|
|
18) Raffaghello L, Bianchi G, Pistoia V, et al. Human mesenchymal stem cells inhibit neutrophil apoptosis: A model for neutrophil preservation in the bone marrow niche. Stem Cells. 2008; 26: 151-62
|
|
|
|
|
|
19) Khakoo AY, Pati S, Finlcel T, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med. 2006; 203: 1235-47
|
|
|
|
|